Source:http://linkedlifedata.com/resource/pubmed/id/12779137
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2003-6-3
|
pubmed:abstractText |
Although the antiplatelet agent clopidogrel is associated with an increased incidence of thrombotic thrombocytopenic purpura (TTP), available evidence is not sufficient to establish or disprove a causal relationship. We review and assess the evidence and case reports linking clopidogrel use with TTP and discuss how to approach the risk of TTP in patients taking clopidogrel.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0891-1150
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
70
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
466-70
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading | |
pubmed:year |
2003
|
pubmed:articleTitle |
Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for causality.
|
pubmed:affiliation |
Department of Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
|
pubmed:publicationType |
Journal Article,
Review
|